Kirk’s YouTube overview of his interview with Jeanne Drisko, MD (7:23)
“Intravenous Vitamin C – Integrative Therapies” a first-time conference sponsored by the University of Kansas Medical Center Department of Integrative Medicine and the University of Kansas Medical Center Continuing Education and Professional Development will be held on September 30 – October 1, 2016. (See Conference Flyer). You can register online at www.KUMC.edu/VitaminC .
This conference will focus on the science and clinical use of intravenous vitamin C as an adjunctive cancer treatment along with chemo and radiation therapies, and discuss research on its safe and beneficial use in treating and preventive sepsis in the ICU setting.
The following is the list of speakers over the two day conference and medical references supporting their topic of discussion and their work.
Friday, September 30, 2016
Qi Chen, Ph.D. (8:30 a.m. ) “High-dose parenteral ascorbate enchanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Science Translational Medicine. 2014, 6, 222ra18.” “Pharmacologic doses of ascorbate act as a pro-oxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA. 2008; 105 (32): 11105-9.
Lewis Cantley, M.D. (9:30 a.m.) “Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.” Science. 2015 Dec 11;350(6266):1391-6.
Daniel Monti, M.D. (11:00 a.m.) “Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity.” Free Radic Biol Med. 2016 Jun;95:308-22.” “Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.” PLoS One. 2012;7(1):e29794.”
Luncheon Panel Discussion: Lewis Cantley, Keynote Speaker Mark Levine, Qi Chen, Dan Monti – Moderator Jeanne Drisko
Mark Levine, M.D. (1:00 p.m. Keynote Speaker) – “Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity.” Free Radic Biol Med. 2016 Jun;95:308-22.; “Low Red Blood Cell Vitamin C Concentrations Induce Red Blood Cell Fragility: A Link to Diabetes Via Glucose, Glucose Transporters, and Dehydroascorbic Acid.” EBioMedicine. 2015 Oct 3;2(11):1735-50.; Vitamin C: the known, the unknown, and Goldilocks. Oral Dis. 2016 Jan 25. doi: 10.1111/odi.12446. [Epub ahead of print]; “Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model.” Free Radic Biol Med. 2015 Oct;87:193-203.; “High-dose ascorbate with low-dose amphotericin B attenuates severity of disease in a model of the reappearance of candidemia during sepsis in the mouse.” Am J Physiol Regul Integr Comp Physiol. 2015 Aug 1;309(3):R223-34.“High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy.” Sci Transl Med. 2014 Feb 5;6(222):222ra18; “The human sodium-dependent ascorbic acid transporters SLC23A1 and SLC23A2 do not mediate ascorbic acid release in the proximal renal epithelial cell.” Physiol Rep. 2013 Nov;1(6):e00136; “Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics.” Antioxid Redox Signal. 2013 Dec 10;19(17):2141-56; “Standard-dose vs high-dose multivitamin supplements for HIV.” JAMA. 2013 Feb 13;309(6):545-6.; “Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.” Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75.; “Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo.” Leuk Lymphoma. 2013 May;54(5):1069-78.;”Vitamin C in mouse and human red blood cells: an HPLC assay.” Anal Biochem. 2012 Jul 15;426(2):109-17.; “Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries.” Adv Nutr. 2011 Mar;2(2):78-88.; “Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.” PLoS One. 2012;7(1):e29794.; “Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer.” Free Radic Biol Med. 2011 Jun 1;50(11):1610-9.; “Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects.” PLoS One. 2010 Jul 7;5(7):e11414. “Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer.” In Vivo. 2010 May-Jun;24(3):249-55.
Jeanne Drisko, M.D. (2:30 p.m. – Topic: ” ‘Clinical Pearls’ and practical application of administering intravenous vitamin C in the clinical setting. “High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy.” Sci Transl Med. 2014 Feb 5;6(222):222ra18.; “Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy.” Anticancer Drugs. 2012 Apr;23(4):437-44.
(Listen to all 5 podcasts with Dr. Drisko on IV Vitamin C and Cancer).
Alpha Fowler, M.D. (3:30 p.m. -– Topic: Use of Vitamin C in Sepsis) Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis J Transl Med. 2014; 12: 32. (Kirk’s Expert Interview with Dr. Fowler and Sepsis)
Ramesh Nataragan, Ph.D. (4:30 p.m. – Topic: How Vitamin C Works in the Septic Patient): “Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock?” Crit Care. 2015 Nov 27;19:418.
Saturday, October 1, 2016
Joseph Cullen, M.D. (8:30 a.m.) “Treatment of Pancreatic Cancer with Pharmacological Ascorbate.” Curr Pharm Biotechnol. 2015;16(9):759-70. 51302
Gary Buettner, Ph.D. (9:30 am.) “Ascorbic acid: chemistry, biology and the treatment of cancer.” Biochim Biophys Acta (2012) 1826(2):443–57.
John Hoffer, M.D. (10:30 a.m.) “A simple method for plasma total vitamin C analysis suitable for routine clinical laboratory use” Nutr J. 2015; 15: 40. “High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma”Yonsei Med J. 2015 September 1; 56(5): 1449–1452. “High-Dose Intravenous Vitamin C Combined with Cytotoxic chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial” PLoS One. 2015; 10(4): e0120228. “Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review,” Oncologist. 2015 February; 20(2): 210–223.
Be and Stay Well,
You may call Kirk Hamilton PA-C Monday thru Friday 8-9 a.m. PST at 916-489-4400 for brief medical questions at Health Associates Medical Group. (for information about Health Associates go to KwikerMedical.com)